2024
P-008 A Rare and Unexplored Entity of Colitis Post-BCMA Directed CAR T-Cell Therapy; Insights From a Multicenter Case Series
Bar N, Yee A, Dhakal B, Frigault M, Richard S, Cohen A, Susanibar-Adaniya S, Rossi A, Vogl D. P-008 A Rare and Unexplored Entity of Colitis Post-BCMA Directed CAR T-Cell Therapy; Insights From a Multicenter Case Series. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s44-s45. DOI: 10.1016/s2152-2650(24)01911-6.Peer-Reviewed Original ResearchAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucel
2023
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Cost P, Schecter J, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Lopez-Muñoz N. Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison. Blood 2023, 142: 2141. DOI: 10.1182/blood-2023-182141.Peer-Reviewed Original ResearchIndividual patient-level dataMatching-adjusted indirect comparisonProgression-free survivalRefractory multiple myelomaCARTITUDE-1Overall response rateMultiple myelomaUnanchored matching-adjusted indirect comparisonIdecabtagene vicleucelHazard ratioCAR-TsKaplan-MeierComparative efficacyIndirect comparisonConfidence intervalsChimeric antigen receptor T-cell therapyB-cell maturation antigenCox proportional hazards modelGood partial responseTreatment of patientsT-cell therapyWeighted logistic regression analysisProportional hazards modelPatient-level dataLogistic regression analysis